PHAS Stock - PhaseBio Pharmaceuticals, Inc.
Unlock GoAI Insights for PHAS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|
| Revenue | $10,831 | $320,000 | $2.36M | $668,000 | N/A |
| Gross Profit | $10,831 | $320 | $2.36M | $668,000 | N/A |
| Gross Margin | 100.0% | 0.1% | 100.0% | 100.0% | N/A |
| Operating Income | $-130,418 | $-84,856,000 | $-39,736,000 | $-19,644,000 | $-8,538,000 |
| Net Income | $-131,071 | $-98,565,000 | $-39,247,000 | $-23,846,000 | $-10,247,000 |
| Net Margin | -1210.1% | -30801.6% | -1662.3% | -3569.8% | N/A |
| EPS | $-0.00 | $-3.39 | $-1.43 | $-4.49 | $-0.91 |
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 28th 2022 | Stifel | Downgrade | Hold | $1← $15 |
Earnings History & Surprises
PHASEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2023 | Mar 22, 2023 | — | — | — | — |
Q4 2022 | Nov 8, 2022 | $-0.35 | — | — | — |
Q3 2022 | Aug 12, 2022 | $-0.31 | $-0.34 | -9.7% | ✗ MISS |
Q2 2022 | May 16, 2022 | $-0.66 | $-0.23 | +65.2% | ✓ BEAT |
Q1 2022 | Mar 24, 2022 | $-0.59 | $-0.90 | -52.5% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.61 | $-0.66 | -8.2% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-0.46 | $-0.60 | -30.4% | ✗ MISS |
Q2 2021 | May 13, 2021 | $-0.73 | $-0.87 | -19.2% | ✗ MISS |
Q1 2021 | Mar 15, 2021 | $-0.70 | $-1.03 | -47.1% | ✗ MISS |
Q4 2020 | Nov 12, 2020 | $-0.77 | $-0.86 | -11.7% | ✗ MISS |
Q3 2020 | Aug 11, 2020 | $-0.52 | $-0.98 | -88.5% | ✗ MISS |
Q2 2020 | May 12, 2020 | $-0.37 | $-0.52 | -40.5% | ✗ MISS |
Q4 2019 | Dec 31, 2019 | — | $-0.39 | — | — |
Q4 2019 | Nov 14, 2019 | $-0.37 | $-0.40 | -8.1% | ✗ MISS |
Q3 2019 | Aug 13, 2019 | $-0.32 | $-0.33 | -3.1% | ✗ MISS |
Q2 2019 | May 9, 2019 | $-0.41 | $-0.30 | +26.8% | ✓ BEAT |
Q1 2019 | Mar 26, 2019 | $-0.30 | $-0.26 | +13.3% | ✓ BEAT |
Q4 2018 | Nov 29, 2018 | $-0.48 | $-10.45 | -2077.1% | ✗ MISS |
Q2 2018 | Jun 30, 2018 | — | $-0.34 | — | — |
Q1 2018 | Mar 31, 2018 | — | $-0.36 | — | — |
Latest News
Frequently Asked Questions about PHAS
What is PHAS's current stock price?
What is the analyst price target for PHAS?
What sector is PhaseBio Pharmaceuticals, Inc. in?
What is PHAS's market cap?
Does PHAS pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to PHAS for comparison